Pharmacogenetic predictors of the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode
- Autores: Ivashchenko D.V.1,2, Buromskaya N.I3, Shimanov P.V3, Deich R.V3, Dorina I.V3, Nastovich M.I3, Akmalova K.A1, Kachanova A.A1, Grishina E.A1, Savchenko L.M1, Shevchenko Y.S1, Sychev D.A1
-
Afiliações:
- Russian Medical Academy of Continuous Professional Education
- Penza Institute for Advanced Training of Doctors - Branch of Russian Medical Academy of Continuous Professional Education
- G.E. Sukharev Scientific and Practical Center for Mental Health of Children and Adolescents
- Edição: Volume 28, Nº 11 (2021)
- Páginas: 77-83
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313280
- DOI: https://doi.org/10.18565/pharmateca.2021.11.77-83
- ID: 313280
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
Dmitry Ivashchenko
Russian Medical Academy of Continuous Professional Education; Penza Institute for Advanced Training of Doctors - Branch of Russian Medical Academy of Continuous Professional Education
Email: dvi1991@yandex.ru
Senior Researcher, Research Institute for Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education ; Associate Professor at the Department of Psychiatry, Psychiatry-Narcology and Psychotherapy, Penza Institute for Advanced Medical Education - Branch Campus of the Russian Medical Academy of Continuous Professional Education Moscow, Russia
N. Buromskaya
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
P. Shimanov
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
R. Deich
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
I. Dorina
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
M. Nastovich
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
K. Akmalova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
A. Kachanova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
E. Grishina
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
L. Savchenko
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
Yu. Shevchenko
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
D. Sychev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
Bibliografia
- Abidi S. Psychosis in children andyouth: focus on early-onset schizophrenia. Pediatr Rev. 2013;34(7):296-305. doi: 10.1542/pir.34-7-296.
- Haddad P.M., Correll C.U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303-18. doi: 10.1177/2045125318781475.
- Kahn R.S., Fleischhacker W.W., Boter H., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-97. doi: 10.1016/S0140-6736(08)60486-9.
- Chan V. Schizophrenia and Psychosis: Diagnosis, Current Research Trends, and Model Treatment Approaches with Implications for Transitional Age Youth. Child Adolesc Psychiatr Clin N Am. 2017;26(2):341-66. Doi: 10.1016/j. chc.2016.12.014.
- Martinuzzi E., Barbosa S., Daoudlarian D., et al. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatr. 2019;9(1):20. Doi: 10.1038/ s41398-018-0366-5.
- Cacabelos R., Hashimoto R., Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatr Clin Neurosci. 2011;65(1):3-doi: 10.1111/j.1440-1819.2010.02168.x.
- Gründer G., Heinze M., Cordes J., et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet. Psychiatr. 2016;3(8):717-29. doi: 10.1016/S2215-0366(16)00085-7.
- Maayan L., Correll C.U. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517-35. doi: 10.1089/cap.2011.0015.
- Schneider C., Taylor D., Zalsman G., et al. Antipsychotics use in children and adolescents: An on-going challenge in clinical practice. J Psychopharmacol. 2014;28(7):615-23. doi: 10.1177/0269881114533599.
- Datta S.S., Kumar A., Wright S.D., et al. Evidence base for using atypical antipsychotics for psychosis in adolescents. Schizophr Bull. 2014;40(2):252-54.
- Minjon L., van den Ban E., de Jong E., et al. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics. J Child Adolesc Psychopharmacol. 2019;29(2):124-32. doi: 10.1089/cap.2018.0139.
- Bai Y., Liu T., Xu A., et al. Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. Expert Opin Drug Saf. 2019;18(8):703-17. doi: 10.1080/14740338.2019.1632832.
- Stafford M.R., Mayo-Wilson E., Loucas C.E., et al. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and metaanalysis. PLoS One. 2015;10(2):e0117166. doi: 10.1371/journal.pone.0117166.
- Bioque M., Llerena A., Cabrera B., et al. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. Int J Neuropsychopharmacol. 2016;19(4):121. doi: 10.1093/ijnp/pyv121.
- van Westrhenen R., Aitchison K.J., Ingelman-Sundberg M., et al. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Front. Psychiatr. 2020;11:94. Doi: 10.3389/ fpsyt.2020.00094.
- Wehry A.M., Ramsey L., Dulemba S.E., et al. Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. Curr Probl Pediatr Adolesc. Health Care. 2018;48(2):40-9. doi: 10.1016/j.cppeds.2017.12.003.
- Maruf A.A., Stein K., Arnold P.D., et al. CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. J Child Adolesc Psychopharmacol. 2021;31(1):33-45. doi: 10.1089/cap.2020.0093.
- Иващенко Д.В., Буромская Н.И., Шиманов П.В. и др. Полиморфный вариант HTR2A rs6313 ассоциирован с нежелательными реакциями на антипсихотики у подростков с острым психотическим эпизодом. Фарматека. 2021;28(9):45-51
- Иващенко Д.В., Петунова Ю.Л. и др. Полиморфные варианты генов ANKS1B rs7968606 (C>T) и ZNF804A rs1344706 (G>T) не ассоциированы с эффективностью и безопасностью применения антипсихотиков у подростков с острым психотическим эпизодом. Фарматека. 2021;28(9):28-33
- Иващенко Д.В., Иванюта М.В., Буромская Н.И. и др. Носительство полиморфного варианта COMT rs4680 ассоциировано с лучшей переносимостью антипсихотиков у подростков с острым психотическим эпизодом: проспективное обсервационное клиническое исследование. Фарматека. 2021;28(3):62-7
- Иващенко Д.В., Федина Л.В., Юделевич Д.А. и др. Полиморфные варианты генов рецепторов дофамина DRD2, DRD3 и DRD4 ассоциированы с ранней эффективностью и безопасностью антипсихотиков у подростков с острым психотическим эпизодом. Клиническая фармакология и терапия. 2021;30(2):75-80
- Ivashchenko D.V., Khoang S.Z., Makhmudova B.V., et al. Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. Drug Metab Pers Ther. 2020;4(35):20200102. doi: 10.1515/dmpt-2020-0102.
- Jallaq S.A., Verba M., Strawn J.R., et al. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. J Child Adolesc Psychopharmacol. 2021;31(1):56-62. doi: 10.1089/cap.2020.0058.
- Oshikoya K.A., Neely K.M., Carroll R.J., et al. CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res. 2019;85(5):602-6. doi: 10.1038/s41390-019-0305-z.
- Youngster I., Zachor D.A., Gabis L.V., et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study Dev Med Child Neurol. 2014;56(10):990-94. Doi: 10.1111/ dmcn.12470.
- Gradinaru R., Andreescu N., Nussbaum L., et al. Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. Ir J Med Sci. 2019;188(4):1417-doi: 10.1007/s11845-019-01985-x.
- Brown J.T., Campo-Soria C., Bishop J.R. Current strategies for predicting side effects from second generation antipsychotics in youth. Expert Opin Drug Metab Toxicol. 2021;17(6):655-64. doi: 10.1080/17425255.2021.1922668.